An everyday clinical challenge in the COVID 19 pandemic era – how to treat patients with pulmonary embolism and hemoptysis

COVID 19 and pulmonary embolism

  • Duska Clinic for Infective Diseases, University Clinical Center Nis, Nis, Serbia
  • Milovan M Stojanović Institut za lečenje i rehabilitaciju Niška Banja
  • Dusan Clinic for Infective Diseases, University Clinical Center Nis, Nis, Serbia
  • Goran Clinic for Infective Diseases, University Clinical Center Nis, Nis, Serbia
  • Marko Faculty of Medicine, Nis University
  • Vida Military hospital Vranje
DOI: https://doi.org/10.5937/halo28-35541
Ključne reči: plućna embolija, COVID 19, antikoagulansi, hemoptizije

Sažetak


Uvod. Plućna embolija (PE) je relativno česta komplikacija COVID-a 19. Kamen temeljac lečenja PE je antikoagulantna terapija. Međutim, antikoagulansi mogu izazvati ozbiljno krvarenje. Pacijente sa PE i hemoptizijama je često veoma teško lečiti.

Prikaz bolesnika. Predstavili smo slučaj mladog pacijenta koji je dobio upalu pluća izazvanu COVID 19. Tokom bolničkog lečenja, kod bolesnika je došlo do razvoja PE zbog čega je povećana doza antikoagulansa. Ubrzo nakon povećanja doze, pacijent je dobio masivnu hemoptiziju. Tim lekara je odlučio da nastavi sa antikoagulansima i da u terapiju uvede hemostatik. Pacijent je dobro oreagovao na terapiju i otpušten je iz bolnice posle dve nedelje lečenja.

Zaključak. Pacijente sa PE i hemoptizijama je često teško lečiti jer lečenje PE može pogoršati hemoptizije. Zbog toga odluku o lečenju ovakvih bolesnika treba da donese tim lekara.

Reference


  1. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020; 191: 145-7. doi: 10.1016/j.thromres.2020.04.013.

  2. Goeijenbier M, van Wissen M, van de Weg C, Jong E, Gerdes VE, Meijers JC, et al. Review: Viral infections and mechanisms of thrombosis and bleeding. J Med Virol. 2012; 84(10): 1680-96. doi: 10.1002/jmv.23354.

  3. Hess DC, Eldahshan W, Rutkowski E. COVID-19-Related Stroke. Transl Stroke Res. 2020; 11(3): 322-5. doi: 10.1007/s12975-020-00818-9.

  4. Davoodi L, Jafarpour H, Taghavi M, Razavi A. COVID-19 Presented With Deep Vein Thrombosis: An Unusual Presenting. J Investig Med High Impact Case Rep. 2020; 8: 2324709620931239. doi: 10.1177/2324709620931239.

  5. Stefanini GG, Montorfano M, Trabattoni D, Andreini D, Ferrante G, Ancona M, et al. ST-Elevation Myocardial Infarction in Patients With COVID-19: Clinical and Angiographic Outcomes. Circulation. 2020; 141(25): 2113-26. doi: 10.1161/CIRCULATIONAHA.120.047525.

  6. Léonard-Lorant I, Delabranche X, Séverac F, Helms J, Pauzet C, Collange O, et al. Acute Pulmonary Embolism in Patients with COVID-19 at CT Angiography and Relationship to d-Dimer Levels. Radiology. 2020; 296(3): E189-91. doi: 10.1148/radiol.2020201561.

  7. Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J. 2020; 41(19): 1858. doi: 10.1093/eurheartj/ehaa254.

  8. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al.; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020; 41(4): 543-603. doi: 10.1093/eurheartj/ehz405.

  9. Lauzier F, Arnold DM, Rabbat C, Heels-Ansdell D, Zarychanski R, Dodek P, et al. Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis. Intensive Care Med. 2013; 39(12): 2135-43. doi: 10.1007/s00134-013-3044-3.

  10. Lippi G, Favaloro EJ. d-Dimer is associated with severity of coronavirus disease 2019: a pooled analysis. Thromb Haemost. 2020; 120(5): 876–8. doi: 10.1055/s-0040-1709650.

  11. Sakr Y, Giovini M, Leone M, Pizzilli G, Kortgen A, Bauer M, et al. Pulmonary embolism in patients with coronavirus disease-2019 (COVID-19) pneumonia: a narrative review. Ann Intensive Care. 2020; 10: 124. doi: 10.1186/s13613-020-00741-0.

  12. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al.; Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020; 75(23): 2950-73. doi: 10.1016/j.jacc.2020.04.031.

  13. Suh YJ, Hong H, Ohana M, Bompard F, Revel MP, Valle C, et al. Pulmonary Embolism and Deep Vein Thrombosis in COVID-19: A Systematic Review and Meta-Analysis. Radiology. 2021; 298(2): E70-80. doi: 10.1148/radiol.2020203557.

  14. Scudiero F, Silverio A, Di Maio M, Russo V, Citro R, Personeni D, et al.; Cov-IT Network. Pulmonary embolism in COVID-19 patients: prevalence, predictors and clinical outcome. Thromb Res. 2021; 198: 34-9. doi: 10.1016/j.thromres.2020.11.017.

  15. Bidwell JL, Pachner RW. Hemoptysis: diagnosis and management. Am Fam Physician. 2005; 72(7): 1253-60.

  16. Sakr L, Dutau H. Massive hemoptysis: an update on the role of bronchoscopy in diagnosis and management. Respiration. 2010; 80(1): 38-58. doi: 10.1159/000274492.

  17. Earwood JS, Thompson TD. Hemoptysis: evaluation and management. Am Fam Physician. 2015; 91(4): 243-9.

  18. Stein PD, Terrin ML, Hales CA, Palevsky HI, Saltzman HA, Thompson BT, et al. Clinical, laboratory, roentgenographic, and electrocardiographic findings in patients with acute pulmonary embolism and no pre-existing cardiac or pulmonary disease. Chest. 1991; 100(3): 598-603. doi: 10.1378/chest.100.3.598.

  19. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497-506. doi: 10.1016/S0140-6736(20)30183-5.

Objavljeno
2022/03/29
Broj časopisa
Vol. 28 Br. 1 (2022): Naučni časopis urgentne medicine Halo 194
Rubrika
Prikaz bolesnika
Autori koji objavljuju u ovom časopisu pristaju na sledeće uslove:

  1. Autori zadržavaju autorska prava i pružaju časopisu pravo prvog objavljivanja rada i licenciraju ga "Creative Commons Attribution licencom" koja omogućava drugima da dele rad, uz uslov navođenja autorstva i izvornog objavljivanja u ovom časopisu.

  2. Autori mogu izraditi zasebne, ugovorne aranžmane za neekskluzivnu distribuciju članka objavljenog u časopisu (npr. postavljanje u institucionalni repozitorijum ili objavljivanje u knjizi), uz navođenje da je članak izvorno objavljen u ovom časopisu.

  3. Autorima je dozvoljeno i podstiču se da postave objavljeni članak onlajn (npr. u institucionalni repozitorijum ili na svoju internet stranicu) pre ili tokom postupka prijave rukopisa, s obzirom da takav postupak može voditi produktivnoj razmeni ideja i ranijoj i većoj citiranosti objavljenog članka (Vidi Efekti otvorenog pristupa).